Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL673043 | 1.00 | THRB (0.53) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL671674 | 1.00 | THRB (0.53) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL212008 | 0.98 | THRB (0.55) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL4294879 | 0.92 | THRB (0.47) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL21385092 | 0.92 | THRB (0.52) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL10427136 | 0.92 | TSHR (0.53) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL10427163 | 0.92 | TSHR (0.53) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL10427274 | 0.92 | THRB (0.55) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL10150598 | 0.90 | TSHR (0.56) | THRBTSHRALDH1A1POLBAPEX1 | |
| SCHEMBL4536017 | 0.90 | THRB (0.48) | THRBTSHRALDH1A1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6194511-B1 | COMPRISING POLYMERIZABLE MONOMER CONTAINING SULFUR-CONTAINING (METH)ACRYLATE POLYMERIZABLE MONOMER AND PHOTOCHROMIC COMPOUND | TOKUYAMA CORPORATION (JP) | 2001-02-27 | — | — | US | claimed |
| EP-3901185-B1 | CURABLE COMPOSITION FOR OPTICAL MATERIALS, AND OPTICAL MATERIAL | TOKUYAMA CORP (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-4696722-A1 | (METH)ACRYLATE, CURABLE COMPOSITION, CURED BODY, LAMINATE, OPTICAL ARTICLE, LENS, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-12552745-B2 | Compound for optical materials, curable composition, cured body, and optical article | TOKUYAMA CORPORATION (JP) | 2026-02-17 | — | — | US | disclosed |
| EP-4644435-A1 | URETHANE (METH)ACRYLATE, CURABLE COMPOSITION, CURED BODY, LAMINATE, OPTICAL ARTICLE, LENSES, AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2025-11-05 | — | — | EP | disclosed |
| EP-4636466-A1 | CURABLE COMPOSITION, CURED BODY, LAMINATE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2025-10-22 | — | — | EP | disclosed |
| EP-4636465-A1 | CURABLE COMPOSITION, CURED BODY, LAMINATE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2025-10-22 | — | — | EP | disclosed |
| EP-4636464-A1 | CURABLE COMPOSITION, CURED BODY, LAMINATE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-12428517-B2 | Moisture curable polyurethane composition and laminate | TOKUYAMA CORPORATION (JP) | 2025-09-30 | — | — | US | disclosed |
| US-12428390-B2 | Chromene compound and photochromic optical article | TOKUYAMA CORPORATION (JP) | 2025-09-30 | — | — | US | disclosed |
| EP-1130038-B1 | PHOTOCHROMIC CURABLE COMPOSITION | TOKUYAMA CORP (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20050263745-A1 | Method of preparing a ceramic artificial crown and a preparation kit used therefor | TOKUYAMA CORPORATION (JP) | 2005-12-01 | — | — | US | disclosed |
| EP-1291388-B1 | CURABLE COMPOSITION AND PHOTOCHROMIC CURED ARTICLE | TOKUYAMA CORP (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-6698883-B2 | COLOR DENSITY AND A LARGE FADING RATE, HARDNESS, HEAT RESISTANCE AND SHOCK RESISTANCE; AS OPTICAL MATERIAL SUCH AS A PHOTOCHROMIC LENS MATERIAL | TOKUYAMA CORPORATION (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1291388-A1 | CURABLE COMPOSITION AND PHOTOCHROMIC CURED ARTICLE | TOKUYAMA CORPORATION (JP) | 2003-03-12 | — | — | EP | disclosed |
| US-20030008958-A1 | Curable composition and photochromic cured article | TOKUYAMA CORPORATION (JP) | 2003-01-09 | — | — | US | disclosed |
| EP-0940694-B1 | Photochromic curable composition | TOKUYAMA CORP (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-1130038-A1 | CURABLE COMPOSITION | TOKUYAMA CORPORATION (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6194511-B1 | COMPRISING POLYMERIZABLE MONOMER CONTAINING SULFUR-CONTAINING (METH)ACRYLATE POLYMERIZABLE MONOMER AND PHOTOCHROMIC COMPOUND | TOKUYAMA CORPORATION (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0940694-A1 | Photochromic curable composition | TOKUYAMA CORPORATION (JP) | 1999-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552745-B2 | Compound for optical materials, curable composition, cured body, and optical article | C5, SCO2, ZYX | THRB 2158/4885TSHR 3533/4885ALDH1A1 1308/4885 |
| US-12428390-B2 | Chromene compound and photochromic optical article | CRY1, CRY2, RAD51 | THRB 2407/4885TSHR 2223/4885ALDH1A1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.